Physician profile
Manuel Gigena
NPI 1487834792
$1,556.54
in general payments reported to CMS, 2019-2025
16 companies · $33.91 in 2025
The $33.91 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $125 · 2021: $195 · 2022: $461 · 2023: $58.37 · 2024: $58.57 · 2025: $33.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $456.64 | 2019 | |
| Sientra, INC. | $375.77 | 2020-2022 | |
| Acera Surgical, INC. | $275.22 | 2021-2023 | Restrata Wound Matrix |
| Allergan, INC. | $72.60 | 2019 | |
| Boston Scientific Corporation | $63.85 | 2020 | |
| Smith+Nephew, INC. | $61.50 | 2019-2021 | |
| Merit Medical Systems INC | $51.60 | 2021 | |
| Motiva USA, LLC | $33.91 | 2025 | |
| Mentor Worldwide LLC | $33.65 | 2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Medtronic Vascular, INC. | $31.22 | 2019 | |
| Abbvie INC. | $24.92 | 2024 | |
| Tei Biosciences INC | $17.33 | 2019 | |
| Davol INC. | $16.93 | 2021 | |
| Merz North America, INC. | $15.89 | 2021 | |
| Bioventus LLC | $13.51 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Gigena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.